Amankwah Ernest K, Mosha Maua, Dean Jennifer, Mayer Jennifer
The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Epidemiology and Biostatistics, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA.
BMJ Open. 2025 Jun 6;15(6):e083782. doi: 10.1136/bmjopen-2023-083782.
Medical comorbidity at diagnosis is associated with treatment outcome in cancer. The aim of this project is to synthesise the evidence on the association between medical comorbidities and paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma outcomes.
A systematic review of the literature will be conducted by developing a search strategy that will combine medical subject headings and natural language key words related to acute lymphoblastic leukaemia or lymphoma, medical comorbidities and treatment-related outcomes. We will search MEDLINE and EMBASE to identify studies in human subjects and written in English from the inception of each database to 30 September 2022. Two authors will independently screen the titles and abstracts of retrieved studies based on the inclusion and exclusion criteria to identify potentially eligible studies. Full-text articles of eligible studies and final included articles will be retrieved and reviewed in a similar manner by two independent reviewers. Data extraction from included articles will be conducted independently by two authors using a standardised data extraction form. Risk of bias in the included studies will be assessed using existing relevant tools. A narrative and tabular summary of the data, including outcomes, will be provided if the data do not warrant a meta-analysis. If a meta-analysis is feasible, we will pool all the effect estimates. Heterogeneity among study effect sizes will be tested with Cochran's Q test and quantified by the I statistic.
This study will not include the collection of original data, but it will be a summary of aggregate existing data. Thus, ethics approval is not applicable. The findings of the study will be disseminated through peer-reviewed publications.
CRD42022366669.
癌症诊断时的合并症与治疗结果相关。本项目的目的是综合关于合并症与小儿急性淋巴细胞白血病和淋巴细胞淋巴瘤结局之间关联的证据。
将通过制定检索策略对文献进行系统综述，该策略将结合与急性淋巴细胞白血病或淋巴瘤、合并症及治疗相关结局有关的医学主题词和自然语言关键词。我们将检索MEDLINE和EMBASE，以识别自每个数据库建立至2022年9月30日期间发表的、以英文撰写的关于人类受试者的研究。两名作者将根据纳入和排除标准独立筛选检索到的研究的标题和摘要，以识别潜在符合条件的研究。符合条件的研究的全文文章和最终纳入的文章将由两名独立审稿人以类似方式检索和评审。两名作者将使用标准化数据提取表独立从纳入的文章中提取数据。将使用现有的相关工具评估纳入研究中的偏倚风险。如果数据不支持进行荟萃分析，将提供包括结局在内的数据的叙述性和表格性总结。如果荟萃分析可行，我们将汇总所有效应估计值。将使用Cochran's Q检验检验研究效应大小之间的异质性，并通过I统计量进行量化。
本研究不包括原始数据的收集，而是对现有汇总数据的总结。因此，无需伦理批准。本研究的结果将通过同行评审出版物进行传播。
PROSPERO注册号：CRD42022366669。
